Neurology · USMLE Step 1 and Step 2

Levodopa/Carbidopa song

Levodopa & Carbidopa - Mechanism & Side Effects, as a song. Hear the short teaser here. The full song is on YouTube and Spotify.

Levodopa/Carbidopa

Full song on YouTube ↗Spotify ↗

Key points in this song10

Levodopa is the dopamine precursor that crosses the blood-brain barrier; dopamine itself cannot cross, making levodopa the cornerstone of Parkinson's disease pharmacotherapy.
Carbidopa is a peripheral DOPA decarboxylase inhibitor that prevents conversion of levodopa to dopamine outside the CNS, reducing peripheral side effects and increasing CNS bioavailability of levodopa.
The combination allows a lower dose of levodopa to be used, minimizing peripheral side effects such as nausea, vomiting, and orthostatic hypotension caused by peripheral dopamine.
Long-term levodopa use leads to motor fluctuations including the "wearing-off" effect (end-of-dose deterioration) and dyskinesias, particularly peak-dose choreiform movements.
The "on-off" phenomenon describes unpredictable fluctuations between mobility and immobility seen with prolonged levodopa therapy, thought to result from pulsatile dopamine receptor stimulation.
Levodopa is most effective for bradykinesia and rigidity in Parkinson's disease; tremor responds less reliably compared to the other cardinal features.
Pyridoxine (vitamin B6) enhances peripheral decarboxylase activity and can increase peripheral breakdown of levodopa, reducing its efficacy — this concern is negated when carbidopa is co-administered.
Levodopa is contraindicated with nonselective MAO inhibitors due to risk of hypertensive crisis from excess peripheral catecholamine accumulation.
Antipsychotics that block D2 receptors (e.g., haloperidol, typical antipsychotics) antagonize levodopa's therapeutic effect and are contraindicated in Parkinson's patients; quetiapine or clozapine are preferred if antipsychotics are needed.
Levodopa/carbidopa does not slow disease progression; it remains purely symptomatic treatment, as the underlying nigrostriatal neurodegeneration continues unabated.